



Innovative Medicines Initiative

The revised IMI Scientific Research Agenda

Daan JA Crommelin, PhD, vice chair of the Scientific Committee of the
Innovative Medicines Initiative

Utrecht University, The Netherlands

27 February 2012

Scientific Committee




The Scientific Committee is a body of the IMI Joint Undertaking and provides scientific advice to the Governing Board.

The Scientific Committee is currently composed of 14 scientists/experts from different background (academia, SMEs, 'big pharma', patient organizations, regulators) that have been appointed further to recommendations made by the States Representatives Group.


The Scientific Committee

- gives strategic, science-based recommendations to the IMI JU
- advises on the continued relevance of the Research Agenda and the scientific priorities, which are the basis for Call Topics



Scientific Committee: its role....


Strategic Research Agenda






The Research Agenda 2008/9




- The IMI Research Agenda is a multiannual plan.
- It identifies principal research bottlenecks in the biopharmaceutical R&D process.
- It describes recommendations to overcome these bottlenecks and a plan to guide their implementation.
- It focuses on four areas: predicting safety, predicting efficacy, knowledge management, education and training.
- It is a tool to communicate the IMI mission.



The Original Matrix of the IMI SRA




The Updated Structure of the Revised SRA



Implementing the Revised SRA: the IMI 4th Call for Proposals



- First “Think Big” topics are launched: **EMIF** (€ 24 million from both EFPIA and the public side) and **hiPS** topic (€ 26 million from both EFPIA and public side)
 - In addition, new research areas in **pharmaceutical chemistry, oral drug delivery, binding kinetics, optimising delivery of biological macromolecules** are addressed
 - The topics will continue to bring together data, resources and expertise from the public and private sectors to improve pharmaceutical research
-





Fifth Call






- ***European Lead Factory:***
Joint European Compound Library and Screening Centre


*Subject of today's discussions:
this is not about (lead) plumbing*



SRA and the Scientific Advisory Board..... an evolving relationship



www.UMCUtrecht.nl
0800-250025



Feedback